Form 4: Cytosorbents CFO Exercises Subscription Rights, Acquires Shares and Warrants

Cytosorbents' Chief Financial Officer, Peter J. Mariani, exercised subscription rights to acquire shares and warrants in the company.

Summary

• Peter J. Mariani, the Chief Financial Officer of Cytosorbents Corp, exercised subscription rights on January 17, 2025.
• This exercise resulted in the acquisition of 32,625 shares of common stock, Series A warrants, and Series B warrants.
• The subscription price was $1.00 per unit, totaling $32,625.
• The rights were obtained through a rights offering that closed on January 10, 2025.
• The Series A warrants have an exercise price based on 90% of the 5-day volume weighted average price of the common stock prior to their expiration, with a floor of $1.00 and a ceiling of $2.00.
• The Series A warrants expire 45 days after the closing date of the rights offering.
• The Series B warrants have an exercise price based on 90% of the 5-day volume weighted average price of the common stock prior to their expiration, with a floor of $2.00 and a ceiling of $4.00.
• The Series B warrants expire 90 days after the closing date of the rights offering.
• Mariani also holds 110,000 restricted stock units (RSUs) that vest upon a change in control or the fourth anniversary of the grant date, 65,000 RSUs that vest over two years, and 175,000 RSUs that vest upon a change in control.
• Additionally, Mariani owns 83,988 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine insider transaction, which is generally positive as it shows the CFO's participation in the company's capital raising activities. There are no indications of negative sentiment.

Positives

• The CFO's participation in the rights offering demonstrates confidence in the company's future.
• The exercise of subscription rights provides the company with additional capital.

Risks

• The value of the warrants is dependent on the future performance of the company's stock price.
• The vesting of RSUs is contingent on continued service and/or a change in control, which may not occur.

Future Outlook

The document does not contain any specific forward-looking statements, but the exercise of warrants could lead to further dilution of shares if exercised.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who make transactions in their company's securities. It is a routine disclosure and does not indicate any unusual activity.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The exercise of subscription rights and the acquisition of warrants are common methods for companies to raise capital and incentivize employees.
• The terms of the warrants, with exercise prices tied to the stock's volume-weighted average price, are typical in such offerings.
• Companies like Amgen, Gilead Sciences, and Regeneron also have similar insider transaction filings, reflecting the standard nature of this activity.

Stakeholder Impact

• The exercise of subscription rights may have a minor dilutive effect on existing shareholders.
• The transaction demonstrates the CFO's confidence in the company, which could be viewed positively by investors.

Key Dates

Keywords

subscription rights, warrants, common stock, restricted stock units, insider trading, Cytosorbents, CFO, Peter J. Mariani